Quanterix names Bill Donnelly executive chair

Quanterix (QTRX) Corporation announced a series of leadership and governance enhancements designed to support the Company’s next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company’s Board of Directors, effective immediately. Hampton most recently served as President, Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific. Sachs is the former Chief Medical Officer and Chief Scientific Officer of Thermo Fisher Scientific. The company also announced that Bill Donnelly, previously the non-Executive Chair of the Board, has been appointed Executive Chair, and Jeffrey Elliott, a current member of the Board, has been appointed to the newly created role of Lead Independent Director. As Executive Chair, Donnelly will work closely with the Company’s leadership team and provide support in select strategic and operational areas. This structure enables Chief Executive Officer Masoud Toloue to continue advancing the Company’s key strategic initiatives, including expanding its blood- and tissue-based biomarker menu, launching LucentAD Complete for Alzheimer’s diagnosis, and accelerating growth synergies from the Akoya acquisition. Additionally, Paul Meister and David Walt, Ph.D. are stepping down from the Board after many years of service, effective immediately.